GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sun Biomedical Ltd (ASX:SBN) » Definitions » EV-to-FCF

Sun Biomedical (ASX:SBN) EV-to-FCF : 13.47 (As of Jun. 14, 2024)


View and export this data going back to . Start your Free Trial

What is Sun Biomedical EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sun Biomedical's Enterprise Value is A$9.46 Mil. Sun Biomedical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.70 Mil. Therefore, Sun Biomedical's EV-to-FCF for today is 13.47.

The historical rank and industry rank for Sun Biomedical's EV-to-FCF or its related term are showing as below:

ASX:SBN' s EV-to-FCF Range Over the Past 10 Years
Min: -19.16   Med: -0.31   Max: 2.64
Current: 431.2

During the past 13 years, the highest EV-to-FCF of Sun Biomedical was 2.64. The lowest was -19.16. And the median was -0.31.

ASX:SBN's EV-to-FCF is ranked worse than
96.59% of 381 companies
in the Biotechnology industry
Industry Median: 7.86 vs ASX:SBN: 431.20

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-14), Sun Biomedical's stock price is A$0.00. Sun Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.000. Therefore, Sun Biomedical's PE Ratio for today is N/A.


Sun Biomedical EV-to-FCF Historical Data

The historical data trend for Sun Biomedical's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Biomedical EV-to-FCF Chart

Sun Biomedical Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.60 -13.24 -6.04 -2.15 -1.73

Sun Biomedical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.15 - -1.73 -

Competitive Comparison of Sun Biomedical's EV-to-FCF

For the Biotechnology subindustry, Sun Biomedical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Biomedical's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sun Biomedical's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Sun Biomedical's EV-to-FCF falls into.



Sun Biomedical EV-to-FCF Calculation

Sun Biomedical's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=9.458/0.702
=13.47

Sun Biomedical's current Enterprise Value is A$9.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sun Biomedical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sun Biomedical  (ASX:SBN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sun Biomedical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00/0.000
=N/A

Sun Biomedical's share price for today is A$0.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sun Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sun Biomedical EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Sun Biomedical's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sun Biomedical (ASX:SBN) Business Description

Traded in Other Exchanges
Address
425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

Sun Biomedical (ASX:SBN) Headlines

No Headlines